Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 14, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons regarding the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two specific share-related events:
- Employee Trust Transfer: On July 13, 2005, Abacus (GSK) Trustees Limited transferred 9,550 Ordinary Shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- ADR Dividend Reinvestment: On July 14, 2005, Mrs. P. Phelan acquired a beneficial interest in 0.2418 Ordinary Share ADRs through the reinvestment of dividends paid on July 7, 2005, at a price of $48.3044 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure Rule 3.1.4R(1)(b) and 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of shares held in the GlaxoSmithKline Employee Trust following the July 13 transfer.
- Confirm the impact of the dividend reinvestment plan on the total ADR float.
- Review the full list of directors and connected persons to understand the scope of the GSK Trust beneficiaries.